Der Urologe

, Volume 47, Issue 2, pp 172–181 | Cite as

Das Nebennierenkarzinom

Diagnostik und Therapie
  • S. Johanssen
  • M. Fassnacht
  • D. Brix
  • A.-C. Koschker
  • S. Hahner
  • H. Riedmiller
  • B. Allolio
Übersichten

Abstract

Das Nebennierenkarzinom (ACC, NN-Karzinom) ist eine seltene Erkrankung mit schlechter Prognose. Präoperativ ist eine sorgfältige Hormondiagnostik obligat, da der Hormonstatus das perioperative Management beeinflusst, und um Tumormarker für die Nachsorge zu etablieren. In der Bildgebung sind CT und MRT gleichwertig, wobei für die Differenzierung zwischen benignen und malignen Raumforderungen die Bestimmung des Fettgehalts der Läsion und das Kontrastmittel-Wash-out nach 10 min von großer Bedeutung sind. Der einzig kurative Ansatz besteht in der kompletten chirurgischen Resektion mittels offener Adrenalektomie (in der Regel über einen lateralen oder thorakoabdominellen Zugang). Eine intraoperative Kapselverletzung ist dabei unbedingt zu vermeiden. Allerdings sind auch nach R0-Resektion Rezidive sehr häufig, sodass regelmäßige Nachsorgeuntersuchungen über mindestens 5 Jahre notwendig sind. Bei fortgeschrittenem Nebennierenkarzinom wird eine Therapie mit Mitotane mit oder ohne Kombination mit einer Chemotherapie, vorzugsweise im Rahmen der FIRM-ACT-Studie, durchgeführt.

Schlüsselwörter

Hormondiagnostik Adrenale Bildgebung Offene Adrenalektomie Mitotane FIRM-ACT-Studie 

Adrenocortical carcinoma

Diagnostic work-up and treatment

Abstract

Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis. Preoperatively, a thorough hormonal work-up is mandatory, as the hormonal status may influence the perioperative management and may also provide marker hormones for monitoring of tumour recurrence. CT and MRI are equally sensitive and specific imaging tools for adrenal tumours. For discerning malignancy, assessment of the fat content of the tumour and contrast media wash-out after 10 min are of great value. Complete surgical resection of the tumour offers the only chance for cure. Open adrenalectomy via a flank or thoracoabdominal approach is the standard surgical technique. Intraoperative tumour spillage should be carefully avoided. Even after R0 resection, recurrence of the disease is frequent and regular follow-up for a minimum of 5 years is required. In advanced ACC, the treatment of choice is mitotane with or without cytotoxic chemotherapy (preferably after inclusion into the FIRM-ACT trial).

Keywords

Hormonal work-up Adrenal imaging Open adrenalectomy Mitotane FIRM-ACT study 

Literatur

  1. 1.
    Abraham J, Bakke S, Rutt A et al. (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristin, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94(9): 2333–2343PubMedCrossRefGoogle Scholar
  2. 2.
    Allolio B, Fassnacht M (2006) Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91(6): 2027–2037PubMedCrossRefGoogle Scholar
  3. 3.
    Barzon L, Scaroni C, Sonino N et al. (1999) Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 84: 520–526PubMedCrossRefGoogle Scholar
  4. 4.
    Berruti A, Terzolo M, Sperone P et al. (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12: 657–666PubMedCrossRefGoogle Scholar
  5. 5.
    Boland GW, Lee MJ, Gazelle GS et al. (1998) Characterization of adrenal masses in unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 171(1): 201–204PubMedGoogle Scholar
  6. 6.
    Bonacci R, Gigliotti A, Baudin E et al. (1998) Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM. Br J Cancer 78(4): 546–549PubMedGoogle Scholar
  7. 7.
    Bukowski RM, Wolfe M, Levine HS et al. (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma. J Clin Oncol 11(1): 161–165PubMedGoogle Scholar
  8. 8.
    Decker RA, Elson P, Hogan TF et al. (1991) Eastern Cooperative Oncology Group Study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110(6): 1006–1013PubMedGoogle Scholar
  9. 9.
    DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France; IARC PressGoogle Scholar
  10. 10.
    Fassnacht M, Hahner S, Polat B et al. (2006) Adjuvant radiation therapy of the tumor bed prevents local recurrences in adrenocortical carcinoma. Exp Clin Endocrinol Diabet 114(Suppl 1): 17Google Scholar
  11. 11.
    Fassnacht M, Kenn W, Allolio B (2004) Adrenal tumors: how to establish malignancy? J Endocrinol Invest 27: 387–399PubMedGoogle Scholar
  12. 12.
    Grumbach MM, Biller BM, Braunstein GD et al. (2003) Management of the clinically inapparent adrenal mass („incidentaloma“). Ann Intern Med 138: 424–429PubMedGoogle Scholar
  13. 13.
    Hahner S, Fassnacht M (2005) Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6: 386–394PubMedGoogle Scholar
  14. 14.
    Hennings J, Lindhe Ö, Bergström M et al. (2006) [11C]Metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91: 1410–1414PubMedCrossRefGoogle Scholar
  15. 15.
    Honigschnabl S, Gallo S, Niederle B et al. (2002) How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study. Eur J Radiol 41:113–122PubMedCrossRefGoogle Scholar
  16. 16.
    Khan TS, Imam H, Juhlin C et al. (2000) Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11:1281–1287PubMedCrossRefGoogle Scholar
  17. 17.
    Kirschner LS (2006) Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 91: 14–21PubMedCrossRefGoogle Scholar
  18. 18.
    Koschker AC, Fassnacht M, Hahner S et al. (2006) Adrenocortical carcinoma: Improving patient care by establishing new structures. Exp Clin Endocrinol Diab 114(45): 45–51CrossRefGoogle Scholar
  19. 19.
    Leboulleux S, Dromain G, Bonniaud G et al. (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91: 920–925PubMedCrossRefGoogle Scholar
  20. 20.
    Lee JE, Berger DH, el-Naggar AK et al. (1995) Surcigal management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118: 1090–1098PubMedCrossRefGoogle Scholar
  21. 21.
    NCI (1981) Surveillance, epidemiology and end results: incidence and mortality data 1973-77. Bethesda, Maryland, National Cancer InstituteGoogle Scholar
  22. 22.
    Saeger W (2000) Histopathological classification of adrenal tumours. Eur J Clin Invest 30(Suppl 3): 58–62PubMedCrossRefGoogle Scholar
  23. 23.
    Schlumberger M, Brugieres L, Gicquel C et al. (1991) 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67(12): 2997–3000PubMedCrossRefGoogle Scholar
  24. 24.
    Schteingart DE, Doherty GM, Gauger PG et al. (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12: 667–680PubMedCrossRefGoogle Scholar
  25. 25.
    Terzolo M, Angeli, A, Fassnacht M et al. (2007) Adjuvant mitotane treatment in patients with adrenocortical carcinoma. N Engl J Med 356(23): 2372–2380PubMedCrossRefGoogle Scholar
  26. 26.
    van Slooten H, van Oosterom AT (1983) CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 67(4): 377–379Google Scholar
  27. 27.
    Weiss LM, Medeiros LJ, Vickery AL Jr. (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13(3): 202–206PubMedCrossRefGoogle Scholar
  28. 28.
    Williamson SK, Lew D, Miller GJ et al. (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A Southwest Oncology Group Study. Cancer 88(5): 1159–1165PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  • S. Johanssen
    • 1
  • M. Fassnacht
    • 1
  • D. Brix
    • 2
  • A.-C. Koschker
    • 1
  • S. Hahner
    • 1
  • H. Riedmiller
    • 2
  • B. Allolio
    • 1
  1. 1.Schwerpunkt Endokrinologie und Diabetologie, Medizinische Klinik und Poliklinik IUniversitätsklinikWürzburgDeutschland
  2. 2.Urologische Klinik und PoliklinikUniversitätsklinikWürzburgDeutschland

Personalised recommendations